Intellia exits hemophilia B pact with Regeneron; Sangamo targets $24M raise
22 Mar 2024
Gene TherapyLicense out/in
Plus, news about OKYO Pharma:
Intellia departs Regeneron deal:
The CRISPR biotech
disclosed
Friday that it had opted out of a partnership with Regeneron to develop a factor IX gene editing therapy. The partners had penned the deal in 2020, which made Intellia responsible for 35% of development costs in exchange for 35% of profits.
Regeneron in February announced that the FDA had cleared the gene insertion program to be tested in a clinical trial for people with hemophilia B, which is slated to begin in mid-2024. Regeneron can still develop a CRISPR-based factor IX therapy under an earlier licensing agreement, the biotech noted in its SEC filing, making Intellia eligible for up to $320 million in future milestones. Intellia still has 35% stake in a factor XIII insertion program for hemophilia A.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.